Stocksigma LogoStocksigma Logo

Alembic Pharma Receives USFDA Final Approval for Valganciclovir Oral Solution

Alembic Pharmaceuticals secured final USFDA approval for its ANDA for Valganciclovir for Oral Solution, 50 mg/mL, on 27th Oct'26

Alembic Pharma Receives USFDA Final Approval for Valganciclovir Oral Solution

Alembic Pharmaceuticals Ltd 路 Press Release 路 27 Oct 2026, 8:59 pm

Alembic Pharma Receives USFDA Final Approval for Valganciclovir Oral Solution Alembic Pharmaceuticals secured final USFDA approval for its ANDA for Valganciclovir for Oral Solution, 50 mg/mL, on 27th Oct'26. The product is therapeutically equivalent to the RLD, Valcyte for Oral Solution (50 mg/mL) by CHEPLAPHARM Arzneimittel GmbH. The drug is indicated for treating CMV retinitis in AIDS patients and preventing CMV disease in high-risk kidney, heart, or kidney-pancreas transplant recipients. With this clearance, Alembic's cumulative USFDA approvals reach 247 ANDAs, comprising 227 final approvals and 20 tentative approvals.

Original exchange filing (PDF)

More announcements from Alembic Pharmaceuticals Ltd

All Alembic Pharmaceuticals Ltd announcements